China Resources Pharmaceutical Group (HKSE:03320) Interest Expense : HK$-2,610 Mil (TTM As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is China Resources Pharmaceutical Group Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. China Resources Pharmaceutical Group's interest expense for the six months ended in Dec. 2023 was HK$ -977 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-2,610 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. China Resources Pharmaceutical Group's Operating Income for the six months ended in Dec. 2023 was HK$ 6,668 Mil. China Resources Pharmaceutical Group's Interest Expense for the six months ended in Dec. 2023 was HK$ -977 Mil. China Resources Pharmaceutical Group's Interest Coverage for the quarter that ended in Dec. 2023 was 6.83. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

China Resources Pharmaceutical Group Interest Expense Historical Data

The historical data trend for China Resources Pharmaceutical Group's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

China Resources Pharmaceutical Group Interest Expense Chart

China Resources Pharmaceutical Group Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-3,711.02

-3,150.20

-2,747.08

-2,739.82

-2,610.10

China Resources Pharmaceutical Group Semi-Annual Data
	Dec13	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Interest Expense	Get a 7-Day Free Trial															-1,246.13	-1,364.85	-1,439.57	-1,633.40	-976.70

China Resources Pharmaceutical Group Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-2,610 Mil.

China Resources Pharmaceutical Group (HKSE:03320) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

China Resources Pharmaceutical Group's Interest Expense for the six months ended in Dec. 2023 was HK$-977 Mil. Its Operating Income for the six months ended in Dec. 2023 was HK$6,668 Mil. And its Long-Term Debt & Capital Lease Obligation for the six months ended in Dec. 2023 was HK$17,432 Mil.

China Resources Pharmaceutical Group's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Interest Coverage	=	-1	*	Operating Income (Q: Dec. 2023 )	/	Interest Expense (Q: Dec. 2023 )
	=	-1	*	6668.049	/	-976.701
	=	6.83

The higher the ratio, the stronger the company's financial strength is.

China Resources Pharmaceutical Group (HKSE:03320) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » China Resources Pharmaceutical Group Ltd (HKSE:03320) » Definitions » Interest Expense

Traded in Other Exchanges

640:Germany

Address

26 Harbour Road, 41st Floor, China Resources Building, Room 4104-05, Wanchai, HKG

Website

https://www.crpharm.com

CR Pharma, is a vertically integrated conglomerate that operates drug manufacturing, distribution, and retail pharmacy businesses in mainland China. It is the third largest drug distributor by revenue, with a strong presence in Eastern, Northern, and Southern China. Its drug manufacturing segment primarily consists of four listed subsidiaries, Dong E E Jiao, CR Sanjiu, CR Double Crane, and Jiangzhong Pharmaceutical, which are well-known makers of over-the-counter traditional Chinese medicines (or TCM), health supplements, and prescription drugs. We estimate the company's operating income is approximately 53% distribution, 46% manufacturing, and less than 1% retail pharmacies.

Executives

Bei Jing Guo You Zi Ben Yun Ying Guan Li You Xian Gong Si

2201 Interest of corporation controlled by you

China Resources Pharmaceutical Group (HKSE:03320) Headlines

No Headlines